Valneva Launches 60M Euro Share Placement for Vaccine Development

[cafead]

via Valneva SE is initiating a private placement of approximately 60 million euros worth of new ordinary shares to fund its vaccine development programs, including clinical trials for chikungunya, Shigella, and Zika vaccines, and to further commercialize its chikungunya vaccine IXCHIQ®.

article source